TLR9 and glioblastoma: In addition to LPS, CpG oligodeoxynucleotides (CpG-ODN) binding to TLR9 have also been tested for the treatment of glioblastoma patients, but data indicate that only some glioblastoma multiforme patients might benefit from this therapy [7].